IMMX
Immix Biopharma, Inc.NASDAQHealthcare$8.94+3.71%ClosedMarket Cap: $473.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.51
P/S
0.00
EV/EBITDA
-12.30
DCF Value
$2.82
FCF Yield
-5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-101.2%
ROA
-28.1%
ROIC
-31.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-8.1M | $-10.7M | $-0.28 | — |
| FY 2025 | $0.00 | -Infinity% | $-27.2M | $-29.4M | $-0.89 | — |
| Q3 2025 | $0.00 | NaN% | $-7.7M | $-7.6M | $-0.24 | — |
| Q2 2025 | $0.00 | NaN% | $-6.7M | $-6.6M | $-0.22 | — |
| Q1 2025 | $0.00 | NaN% | $-4.7M | $-4.5M | $-0.15 | — |
| Q4 2024 | $0.00 | NaN% | $-5.0M | $-4.8M | $-0.17 | — |
| FY 2024 | $0.00 | NaN% | $-22.7M | $-21.6M | $-0.76 | — |
| Q3 2024 | $0.00 | NaN% | $-7.4M | $-7.1M | $-0.24 | — |
| Q2 2024 | $0.00 | NaN% | $-4.7M | $-4.4M | $-0.15 | — |
| Q1 2024 | $0.00 | NaN% | $-5.6M | $-5.3M | $-0.22 | — |
| Q4 2023 | $0.00 | NaN% | $-5.4M | $-5.1M | $-0.26 | — |
| FY 2023 | $0.00 | NaN% | $-16.1M | $-15.4M | $-0.89 | — |